369 related articles for article (PubMed ID: 34402868)
1. Adverse events with sacubitril/valsartan in the real world: emerging signals to target preventive strategies from the FDA adverse event reporting system.
Gatti M; Antonazzo IC; Diemberger I; De Ponti F; Raschi E
Eur J Prev Cardiol; 2021 Aug; 28(9):983-989. PubMed ID: 34402868
[TBL] [Abstract][Full Text] [Related]
2. Five Years of Sacubitril/Valsartan-a Safety Analysis of Randomized Clinical Trials and Real-World Pharmacovigilance.
Kim YS; Brar S; D'Albo N; Dey A; Shah S; Ganatra S; Dani SS
Cardiovasc Drugs Ther; 2022 Oct; 36(5):915-924. PubMed ID: 34125356
[TBL] [Abstract][Full Text] [Related]
3. Angioedema with sacubitril/valsartan: Trial-level meta-analysis of over 14,000 patients and real-world evidence to date.
Dani SS; Ganatra S; Vaduganathan M
Int J Cardiol; 2021 Jan; 323():188-191. PubMed ID: 32841619
[TBL] [Abstract][Full Text] [Related]
4. Potential Safety Signals for Rhabdomyolysis Associated With High-Potency Statin Use With or Without Sacubitril/Valsartan.
Sunaga T; Ryo Y
Am J Cardiol; 2022 Mar; 166():127-130. PubMed ID: 34963512
[TBL] [Abstract][Full Text] [Related]
5. The real-world safety of sacubitril / valsartan among older adults (≥75): A pharmacovigilance study from the FDA data.
Lerman TT; Greenberg N; Fishman B; Goldman A; Talmor-Barkan Y; Bauer M; Goldberg I; Goldberg E; Kornowski R; Krause I; Levi A; Cohen E
Int J Cardiol; 2024 Feb; 397():131613. PubMed ID: 38030039
[TBL] [Abstract][Full Text] [Related]
6. Cognition- and Dementia-Related Adverse Effects With Sacubitril-Valsartan: Analysis of the FDA Adverse Event Report System Database.
Perlman A; Hirsh Raccah B; Matok I; Muszkat M
J Card Fail; 2018 Aug; 24(8):533-536. PubMed ID: 29746915
[TBL] [Abstract][Full Text] [Related]
7. Updated insights on dementia-related risk of sacubitril/valsartan: A real-world pharmacovigilance analysis.
Chen C; Ding L; Fu F; Xiao J
CNS Neurosci Ther; 2023 Sep; 29(9):2548-2554. PubMed ID: 36971193
[TBL] [Abstract][Full Text] [Related]
8. Diarrhoea with the angiotensin receptor neprilysin inhibitor sacubitril + valsartan: A pharmacovigilance study.
Guion-Firmin J; Tessier S; Lepelley M; Faillie JL; Montastruc JL
Fundam Clin Pharmacol; 2022 Apr; 36(2):378-389. PubMed ID: 34260768
[TBL] [Abstract][Full Text] [Related]
9. Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction.
Solomon SD; McMurray JJV; Anand IS; Ge J; Lam CSP; Maggioni AP; Martinez F; Packer M; Pfeffer MA; Pieske B; Redfield MM; Rouleau JL; van Veldhuisen DJ; Zannad F; Zile MR; Desai AS; Claggett B; Jhund PS; Boytsov SA; Comin-Colet J; Cleland J; Düngen HD; Goncalvesova E; Katova T; Kerr Saraiva JF; Lelonek M; Merkely B; Senni M; Shah SJ; Zhou J; Rizkala AR; Gong J; Shi VC; Lefkowitz MP;
N Engl J Med; 2019 Oct; 381(17):1609-1620. PubMed ID: 31475794
[TBL] [Abstract][Full Text] [Related]
10. Angiotensin Receptor-Neprilysin Inhibition in Acute Myocardial Infarction.
Pfeffer MA; Claggett B; Lewis EF; Granger CB; Køber L; Maggioni AP; Mann DL; McMurray JJV; Rouleau JL; Solomon SD; Steg PG; Berwanger O; Cikes M; De Pasquale CG; East C; Fernandez A; Jering K; Landmesser U; Mehran R; Merkely B; Vaghaiwalla Mody F; Petrie MC; Petrov I; Schou M; Senni M; Sim D; van der Meer P; Lefkowitz M; Zhou Y; Gong J; Braunwald E;
N Engl J Med; 2021 Nov; 385(20):1845-1855. PubMed ID: 34758252
[TBL] [Abstract][Full Text] [Related]
11. Safety of sacubitril/valsartan initiated during hospitalization: data from a non-selected cohort.
López-Azor JC; Vicent L; Valero-Masa MJ; Esteban-Fernández A; Gómez-Bueno M; Pérez Á; Díez-Villanueva P; De-Juan J; Manuel-Iniesta Á; Bover R; Del Prado S; Martínez-Sellés M
ESC Heart Fail; 2019 Dec; 6(6):1161-1166. PubMed ID: 31701680
[TBL] [Abstract][Full Text] [Related]
12. Angioedema in heart failure patients treated with sacubitril/valsartan (LCZ696) or enalapril in the PARADIGM-HF study.
Shi V; Senni M; Streefkerk H; Modgill V; Zhou W; Kaplan A
Int J Cardiol; 2018 Aug; 264():118-123. PubMed ID: 29776559
[TBL] [Abstract][Full Text] [Related]
13. A Pharmacovigilance Study of Adverse Drug Reactions Reported for Cardiovascular Disease Medications Approved Between 2012 and 2017 in the United States Food and Drug Administration Adverse Event Reporting System (FAERS) Database.
Patel NM; Stottlemyer BA; Gray MP; Boyce RD; Kane-Gill SL
Cardiovasc Drugs Ther; 2022 Apr; 36(2):309-322. PubMed ID: 33599896
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and Safety of Sacubitril/Valsartan Therapy for Acute Decompensated Heart Failure with Reduced Ejection Fraction during the Vulnerable Phase: A Multicenter, Assessor-Blinded, Prospective, Observational, Cohort Study.
He Y; Lu X; Zheng Y; Song M; Shen B; Nienaber CA; Chen G; Wu F; Zheng J; Zhang W; Wang Y; Li X; Wen H; Yu X; Zhou Y
Cardiology; 2021; 146(3):335-344. PubMed ID: 33780933
[TBL] [Abstract][Full Text] [Related]
15. Systolic blood pressure, cardiovascular outcomes and efficacy and safety of sacubitril/valsartan (LCZ696) in patients with chronic heart failure and reduced ejection fraction: results from PARADIGM-HF.
Böhm M; Young R; Jhund PS; Solomon SD; Gong J; Lefkowitz MP; Rizkala AR; Rouleau JL; Shi VC; Swedberg K; Zile MR; Packer M; McMurray JJV
Eur Heart J; 2017 Apr; 38(15):1132-1143. PubMed ID: 28158398
[TBL] [Abstract][Full Text] [Related]
16. Sacubitril/valsartan reduces ventricular arrhythmias in parallel with left ventricular reverse remodeling in heart failure with reduced ejection fraction.
Martens P; Nuyens D; Rivero-Ayerza M; Van Herendael H; Vercammen J; Ceyssens W; Luwel E; Dupont M; Mullens W
Clin Res Cardiol; 2019 Oct; 108(10):1074-1082. PubMed ID: 30788621
[TBL] [Abstract][Full Text] [Related]
17. Sacubitril/Valsartan: The Newest Addition to the Toolbox for Guideline-Directed Medical Therapy of Heart Failure.
Rodgers JE
Am J Med; 2017 Jun; 130(6):635-639. PubMed ID: 28285069
[TBL] [Abstract][Full Text] [Related]
18. The safety of sacubitril-valsartan for the treatment of chronic heart failure.
Tyler JM; Teerlink JR
Expert Opin Drug Saf; 2017 Feb; 16(2):257-263. PubMed ID: 28060547
[TBL] [Abstract][Full Text] [Related]
19. Influence of Ejection Fraction on Outcomes and Efficacy of Sacubitril/Valsartan (LCZ696) in Heart Failure with Reduced Ejection Fraction: The Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) Trial.
Solomon SD; Claggett B; Desai AS; Packer M; Zile M; Swedberg K; Rouleau JL; Shi VC; Starling RC; Kozan Ö; Dukat A; Lefkowitz MP; McMurray JJ
Circ Heart Fail; 2016 Mar; 9(3):e002744. PubMed ID: 26915374
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and Safety of Sacubitril/Valsartan in Japanese Patients With Chronic Heart Failure and Reduced Ejection Fraction - Results From the PARALLEL-HF Study.
Tsutsui H; Momomura SI; Saito Y; Ito H; Yamamoto K; Sakata Y; Desai AS; Ohishi T; Iimori T; Kitamura T; Guo W;
Circ J; 2021 Apr; 85(5):584-594. PubMed ID: 33731544
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
